Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity to Asset 0.56
NYSE:NVS's Equity to Asset is ranked lower than
60% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:NVS: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:NVS' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.56
0.51
0.65
Interest Coverage 11.94
NYSE:NVS's Interest Coverage is ranked lower than
71% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. NYSE:NVS: 11.94 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:NVS' s Interest Coverage Range Over the Past 10 Years
Min: 11.93  Med: 16.6 Max: 30.91
Current: 11.94
11.93
30.91
F-Score: 5
Z-Score: 2.30
M-Score: -2.67
WACC vs ROIC
7.51%
7.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.09
NYSE:NVS's Operating margin (%) is ranked higher than
75% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. NYSE:NVS: 17.09 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:NVS' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 20.94 Max: 22.35
Current: 17.09
17.09
22.35
Net-margin (%) 13.69
NYSE:NVS's Net-margin (%) is ranked higher than
75% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:NVS: 13.69 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:NVS' s Net-margin (%) Range Over the Past 10 Years
Min: 13.69  Med: 19.02 Max: 35.29
Current: 13.69
13.69
35.29
ROE (%) 9.12
NYSE:NVS's ROE (%) is ranked higher than
60% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. NYSE:NVS: 9.12 )
Ranked among companies with meaningful ROE (%) only.
NYSE:NVS' s ROE (%) Range Over the Past 10 Years
Min: 9.12  Med: 15.32 Max: 25.73
Current: 9.12
9.12
25.73
ROA (%) 5.14
NYSE:NVS's ROA (%) is ranked higher than
59% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NYSE:NVS: 5.14 )
Ranked among companies with meaningful ROA (%) only.
NYSE:NVS' s ROA (%) Range Over the Past 10 Years
Min: 5.14  Med: 8.97 Max: 16.18
Current: 5.14
5.14
16.18
ROC (Joel Greenblatt) (%) 39.36
NYSE:NVS's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.88 vs. NYSE:NVS: 39.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:NVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.01  Med: 59.62 Max: 69.76
Current: 39.36
36.01
69.76
Revenue Growth (3Y)(%) 1.80
NYSE:NVS's Revenue Growth (3Y)(%) is ranked lower than
61% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:NVS: 1.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:NVS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.9  Med: 4.4 Max: 73.5
Current: 1.8
-3.9
73.5
EBITDA Growth (3Y)(%) -7.20
NYSE:NVS's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. NYSE:NVS: -7.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:NVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.6  Med: 0.8 Max: 82.7
Current: -7.2
-7.6
82.7
EPS Growth (3Y)(%) -6.80
NYSE:NVS's EPS Growth (3Y)(%) is ranked lower than
67% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:NVS: -6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:NVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.1  Med: 3.5 Max: 82
Current: -6.8
-7.1
82
» NYSE:NVS's 10-Y Financials

Financials (Next Earnings Date: 2017-01-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

NVS Guru Trades in Q4 2015

John Rogers 11,267 sh (New)
Jim Simons 3,091,198 sh (+83.74%)
Manning & Napier Advisors, Inc 3,507,436 sh (+26.16%)
Sarah Ketterer 281,710 sh (+7.25%)
Ken Fisher 6,188,893 sh (+0.92%)
Murray Stahl 28,750 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Mairs and Power 4,080 sh (unchged)
Samuel Isaly 895,000 sh (unchged)
John Hussman Sold Out
RS Investment Management Sold Out
PRIMECAP Management 20,768,108 sh (-0.23%)
Dodge & Cox 45,107,085 sh (-1.35%)
Mario Gabelli 7,390 sh (-1.99%)
Tweedy Browne 242,201 sh (-2.74%)
Kahn Brothers 27,643 sh (-3.15%)
» More
Q1 2016

NVS Guru Trades in Q1 2016

Tom Gayner 3,700 sh (New)
John Rogers 13,296 sh (+18.01%)
Sarah Ketterer 316,362 sh (+12.30%)
Jim Simons 3,264,498 sh (+5.61%)
Manning & Napier Advisors, Inc 3,638,373 sh (+3.73%)
Murray Stahl 29,250 sh (+1.74%)
Ken Fisher 6,287,099 sh (+1.59%)
PRIMECAP Management 20,938,858 sh (+0.82%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Dodge & Cox 45,054,916 sh (-0.12%)
Tweedy Browne 237,664 sh (-1.87%)
Mario Gabelli 6,865 sh (-7.10%)
Mairs and Power 3,780 sh (-7.35%)
Samuel Isaly 457,700 sh (-48.86%)
» More
Q2 2016

NVS Guru Trades in Q2 2016

John Rogers 14,818 sh (+11.45%)
Ken Fisher 6,363,641 sh (+1.22%)
Sarah Ketterer 319,351 sh (+0.94%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Mairs and Power 3,780 sh (unchged)
Murray Stahl 29,250 sh (unchged)
PRIMECAP Management 20,831,508 sh (-0.51%)
Dodge & Cox 44,366,511 sh (-1.53%)
Tweedy Browne 233,783 sh (-1.63%)
Manning & Napier Advisors, Inc 3,564,657 sh (-2.03%)
Mario Gabelli 6,015 sh (-12.38%)
Jim Simons 2,260,598 sh (-30.75%)
Samuel Isaly 255,700 sh (-44.13%)
» More
Q3 2016

NVS Guru Trades in Q3 2016

Mairs and Power 6,354 sh (+68.10%)
Jim Simons 2,515,098 sh (+11.26%)
Manning & Napier Advisors, Inc 3,752,105 sh (+5.26%)
Mario Gabelli 6,265 sh (+4.16%)
Sarah Ketterer 321,258 sh (+0.60%)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Murray Stahl 29,250 sh (unchged)
Samuel Isaly 255,700 sh (unchged)
PRIMECAP Management 20,557,433 sh (-1.32%)
Dodge & Cox 43,581,886 sh (-1.77%)
Ken Fisher 6,065,150 sh (-4.69%)
Tweedy Browne 220,115 sh (-5.85%)
John Rogers 13,914 sh (-6.10%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:MRK, NYSE:PFE, NYSE:SNY, NYSE:ABBV, NYSE:BMY, OTCPK:GLAXF, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKF, NYSE:JNJ, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.

Top Ranked Articles about Novartis AG

Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.39
NVS's P/E(ttm) is ranked higher than
55% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. NVS: 25.39 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.96 Max: 29.97
Current: 25.39
5.7
29.97
Forward P/E 13.64
NVS's Forward P/E is ranked higher than
57% of the 63 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. NVS: 13.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.48
NVS's PE(NRI) is ranked higher than
55% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.46 vs. NVS: 25.48 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.24 Max: 31.15
Current: 25.48
10.63
31.15
Price/Owner Earnings (ttm) 18.07
NVS's Price/Owner Earnings (ttm) is ranked higher than
74% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.53 vs. NVS: 18.07 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.75 Max: 23.92
Current: 18.07
7.18
23.92
P/B 2.30
NVS's P/B is ranked higher than
59% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. NVS: 2.30 )
Ranked among companies with meaningful P/B only.
NVS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.47 Max: 3.95
Current: 2.3
1.69
3.95
P/S 3.55
NVS's P/S is ranked lower than
55% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. NVS: 3.55 )
Ranked among companies with meaningful P/S only.
NVS' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.27 Max: 5.01
Current: 3.55
1.89
5.01
PFCF 19.91
NVS's PFCF is ranked higher than
52% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. NVS: 19.91 )
Ranked among companies with meaningful PFCF only.
NVS' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 17.11 Max: 26.69
Current: 19.91
7.05
26.69
POCF 14.45
NVS's POCF is ranked higher than
58% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. NVS: 14.45 )
Ranked among companies with meaningful POCF only.
NVS' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.26 Max: 19.3
Current: 14.45
5.77
19.3
EV-to-EBIT 23.14
NVS's EV-to-EBIT is ranked lower than
54% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.07 vs. NVS: 23.14 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 27.1
Current: 23.14
8.5
27.1
EV-to-EBITDA 15.42
NVS's EV-to-EBITDA is ranked higher than
58% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.70 vs. NVS: 15.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18.4
Current: 15.42
7.3
18.4
Shiller P/E 14.59
NVS's Shiller P/E is ranked higher than
92% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.94 vs. NVS: 14.59 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s Shiller P/E Range Over the Past 10 Years
Min: 9.68  Med: 14.57 Max: 21.52
Current: 14.59
9.68
21.52
Current Ratio 1.05
NVS's Current Ratio is ranked lower than
86% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. NVS: 1.05 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.39 Max: 2.83
Current: 1.05
0.83
2.83
Quick Ratio 0.78
NVS's Quick Ratio is ranked lower than
83% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. NVS: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.13 Max: 2.48
Current: 0.78
0.59
2.48
Days Inventory 136.22
NVS's Days Inventory is ranked lower than
59% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.28 vs. NVS: 136.22 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.85  Med: 155.69 Max: 183.42
Current: 136.22
117.85
183.42
Days Sales Outstanding 62.43
NVS's Days Sales Outstanding is ranked higher than
62% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.78 vs. NVS: 62.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.9 Max: 70.59
Current: 62.43
56.31
70.59
Days Payable 96.14
NVS's Days Payable is ranked higher than
67% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.88 vs. NVS: 96.14 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 96.14
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.90
NVS's Dividend Yield is ranked higher than
91% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVS: 3.90 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.32 Max: 5.11
Current: 3.9
1.47
5.11
Dividend Payout 0.96
NVS's Dividend Payout is ranked higher than
67% of the 386 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. NVS: 0.96 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s Dividend Payout Range Over the Past 10 Years
Min: 0.96  Med: 1.67 Max: 3.22
Current: 0.96
0.96
3.22
Dividend Growth (3y) 5.40
NVS's Dividend Growth (3y) is ranked lower than
56% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.00 vs. NVS: 5.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.8 Max: 18.5
Current: 5.4
0
18.5
Forward Dividend Yield 4.02
NVS's Forward Dividend Yield is ranked higher than
87% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVS: 4.02 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.44
NVS's Yield on cost (5-Year) is ranked higher than
91% of the 791 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. NVS: 5.44 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.05  Med: 4.63 Max: 7.13
Current: 5.44
2.05
7.13
3-Year Average Share Buyback Ratio 0.60
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 435 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. NVS: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.1 Max: 2.4
Current: 0.6
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.92
NVS's Price/Tangible Book is ranked lower than
93% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. NVS: 15.92 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.68  Med: 4.38 Max: 12455
Current: 15.92
2.68
12455
Price/Projected FCF 1.13
NVS's Price/Projected FCF is ranked higher than
81% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. NVS: 1.13 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.14 Max: 2.46
Current: 1.13
0.66
2.46
Price/Median PS Value 1.07
NVS's Price/Median PS Value is ranked higher than
58% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. NVS: 1.07 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.16 Max: 3.1
Current: 1.07
0.64
3.1
Price/Graham Number 4.24
NVS's Price/Graham Number is ranked lower than
79% of the 438 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. NVS: 4.24 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s Price/Graham Number Range Over the Past 10 Years
Min: 1.27  Med: 2.01 Max: 81.67
Current: 4.24
1.27
81.67
Earnings Yield (Greenblatt) (%) 4.28
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. NVS: 4.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 4.28
3.7
11.8
Forward Rate of Return (Yacktman) (%) 4.44
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.15 vs. NVS: 4.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 13.95 Max: 65.9
Current: 4.44
1
65.9

More Statistics

Revenue (TTM) (Mil) $49,634
EPS (TTM) $ 2.85
Beta0.76
Short Percentage of Float0.13%
52-Week Range $66.93 - 88.49
Shares Outstanding (Mil)2,375.50

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 49,460 50,121 53,400
EPS ($) 4.73 4.94 5.68
EPS w/o NRI ($) 4.73 4.94 5.68
EPS Growth Rate
(3Y to 5Y Estimate)
3.45%
Dividends Per Share ($) 2.79 2.89 3.13
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Novartis Is Surviving Oct 03 2016 
A Double Dose of Trouble at Novartis Sep 22 2016 
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
Pharmaceuticals are the New Bonds Aug 30 2016 

More From Other Websites
3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats Dec 09 2016
7 Good Stocks for Your Retirement Portfolio in 2017 Dec 09 2016
8:32 am Novartis AG announces additional analyses from the Phase III MONALEESA-2 study that show... Dec 09 2016
FitBit, Gilead Sciences in Thursday’s 52-Week Low Club Dec 08 2016
Novartis Lung Cancer Drug Beats Chemo in Study Dec 08 2016
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study Dec 07 2016
Sanofi May Battle Johnson & Johnson For European Biotech Actelion Dec 06 2016
Novartis' drug tops chemotherapy in untreated lung cancer patients Dec 06 2016
Exclusive: Novartis in talks to sell some central nervous system drugs - sources Dec 06 2016
Novartis' drug tops standard therapy in untreated lung cancer patients Dec 06 2016
Here is What Hedge Funds Think About Chevron Corporation (CVX) Dec 05 2016
What Smart Money Has To Say About Novartis AG (ADR) (NVS) Dec 05 2016
Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE) Dec 05 2016
Here are 4 Mass. biotechs making noise at the ASH conference so far Dec 05 2016
Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out Dec 05 2016
Novartis CEO plays down prospects for Actelion bid: Blick Dec 04 2016
Novartis CEO plays down prospects for Actelion bid - Blick Dec 04 2016
Novartis says 82 pct of leukemia patients in remission after CAR-T Dec 03 2016
[$$] Our Favorite 10 Stock Picks for 2017 Dec 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)